{"id":1009207,"date":"2026-10-12T08:15:03","date_gmt":"2026-10-12T12:15:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-presents-real-world-data-at-acg-2026-showing-reduced-healthcare-resource-utilization-following-ibsrela-initiation-in-adults-with-ibs-c\/"},"modified":"2026-10-12T08:15:03","modified_gmt":"2026-10-12T12:15:03","slug":"ardelyx-presents-real-world-data-at-acg-2026-showing-reduced-healthcare-resource-utilization-following-ibsrela-initiation-in-adults-with-ibs-c","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-presents-real-world-data-at-acg-2026-showing-reduced-healthcare-resource-utilization-following-ibsrela-initiation-in-adults-with-ibs-c\/","title":{"rendered":"Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA\u00ae Initiation in Adults with IBS-C"},"content":{"rendered":"

\nAdditional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life
\n<\/h2>\n
\n

WALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting showing that gastrointestinal-related healthcare resource utilization (GI-HCRU) dropped significantly after adults with irritable bowel syndrome with constipation (IBS-C) started IBSRELA\u00ae (tenapanor). Ardelyx will also present data on how IBS-C symptom burden affects quality of life, along with the design and rationale of an ongoing Phase 3 study evaluating tenapanor in adults with chronic idiopathic constipation (CIC).<\/p>\n

“IBS-C can affect patients in ways that extend well beyond their symptoms, placing a significant burden on daily life and quality of life, including through ongoing interactions with the healthcare system. We are encouraged by these real-world findings, which show a significant reduction in GI-related healthcare utilization following IBSRELA initiation,” said Rajani Dinavahi, MD, Chief Medical Officer of Ardelyx. “Together with our additional data presented at ACG, these findings reflect our commitment to generating evidence that deepens our understanding of constipation-related disorders, helps inform patient care, and supports continued research into the potential role of tenapanor beyond IBS-C.”<\/p>\n

The data comes from a retrospective, observational real-world analysis of 470 patients with IBS-C who started tenapanor at a national gastroenterology practice. A significant reduction in median GI-related HCRU was observed, from 4.5 visits in the year before tenapanor initiation to 3.0 visits in the year following initiation (3.0 [IQR: 1, 6] vs. 4.5 [IQR: 2, 9]; P<0.001). Significant reductions were also seen in subgroup analyses among patients who had previously tried at least one IBS-C medication, regardless of BMI or comorbidity burden.<\/p>\n

\n
\n Presentations at ACG 2026<\/strong>
\n <\/a>
\n include:<\/strong>\n <\/p>\n\n\n\n\n\n
\n Presentation Title<\/strong>\n <\/td>\n\n Authors<\/strong>\n <\/td>\n\n Poster Number<\/strong>\n <\/td>\n\n Presentation Details<\/strong>\n <\/td>\n<\/tr>\n
Health Care Resource Utilization Decreases Among Patients with Constipation Predominant Irritable Bowel Syndrome Following Initiation of Tenapanor: A Real-World Analysis<\/td>\nKyle Staller, Alan Fossa, Megan O\u2019Byrne, Luisa L. Scott<\/td>\n#P3082<\/td>\nPoster, Oct 12, 1:00 \u2013 2:15 PM CT<\/td>\n<\/tr>\n
A Phase 3, 26-Week Randomized Controlled Study to Assess Safety and Efficacy of Tenapanor for Treatment of Chronic Idiopathic Constipation in Adults: Design and Rationale<\/td>\nSusan Edelstein, Yang Yang, Jocelyn M. Tabora, Kenji Kozuka, Karishma Raju, Anthony J. Lembo.<\/td>\n#P5352<\/td>\nPoster, Oct 13, 1:00 \u2013 2:15 PM CT<\/td>\n<\/tr>\n
High Symptom Severity Burden is Associated with Reduced Quality of Life in US Adults with Irritable Bowel Syndrome with Constipation<\/td>\nMegan Riehl, Taya Westfield, Alan Fossa, Zachary Babcock, Johannah Ruddy, Luisa L. Scott<\/td>\n#P5327<\/td>\nPoster, Oct 13, 1:00 \u2013 2:15 PM CT<\/td>\n<\/tr>\n<\/table>\n

\n
In addition to the poster presentations during ACG, Ardelyx is sponsoring a Product Theater titled \u201cExpanding IBS-C Care with a First-in-Class Treatment,\u201d<\/em><\/strong> on October 12th at 2:30 PM CT, where Dr. Aja McCutchen will lead an engaging clinical discussion on managing adult patients with IBS-C. The session will explore the pathophysiology of IBS-C, examine patient case studies, and discuss practical strategies for identifying when and how to optimize care for patients who may not be achieving adequate symptom relief.<\/p>\n

\n About IBSRELA\u00ae (tenapanor)<\/strong>\n <\/p>\n

IBSRELA\u00ae (tenapanor) is a locally acting inhibitor of the sodium\/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon that is primarily responsible for the absorption of dietary sodium. By inhibiting NHE3, tenapanor reduces the absorption of sodium from the small intestine and colon, retaining luminal water content, accelerating intestinal transit time and resulting in a softer stool consistency. IBSRELA has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and intestinal permeability in animal models. Please see additional full Prescribing Information<\/a>.<\/p>\n

\n About Irritable Bowel Syndrome with Constipation (IBS-C)<\/strong>\n <\/p>\n

Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by abdominal pain and altered bowel movements, estimated to affect 12 million people in the U.S. People living with IBS-C may experience a range of symptoms, including abdominal pain, bloating and infrequent, hard or difficult-to-pass stools. IBS-C can have a significant impact on daily life and is associated with impaired quality of life, reduced productivity, and substantial economic burden.<\/p>\n

\n IMPORTANT SAFETY INFORMATION (IBSRELA)<\/strong>\n <\/p>\n\n\n
\n WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS<\/strong>
\n
IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.<\/td>\n<\/tr>\n<\/table>\n

\n
\n
CONTRAINDICATIONS<\/strong>\n <\/p>\n